Observational analysis showed improved arterial blood gas and reduced non-invasive ventilation in elderly patients with acute COPD exacerbations, suggesting benefits of high-flow therapy.
Objective: To evaluate the efficacy of high-flow nebulized oxygen therapy (HFNC) in restoring respiratory function during acute exacerbations (AECOPD) in elderly patients with chronic obstructive pulmonary disease (COPD), providing clinical guidance for adjusting oxygen therapy regimens. Methods: A total of 100 elderly AECOPD patients admitted between January and December 2024 were randomly assigned into observation and control groups (50 each). The observation group received HFNC therapy, while the control group received conventional nasal cannula oxygen therapy. Comparative analysis was conducted on arterial blood gas parameters (PaO₂, PaCO₂, SaO₂) and respiratory rate (RR) before and 72 hours post-treatment, along with hospitalization duration and non-invasive ventilation (NIV) usage rates. Results: At 72-hour post-treatment, the observation group showed higher PaO₂(86.5±7.3mmHg) SaO₂ (95.4±2.0%) and lower RR (18.0±2.4 vs 52.5±4.3mmHg) (22.8±2.6 vs 24.0). The observation group had shorter hospital stays (8.3±1.5d) (11.4±1.9d) and lower NIV usage rate (8.0% vs 24.0%), all with statistically significant differences (P<0.05). Conclusion: HFNC can improve the arterial blood gas status of elderly AECOPD patients, reduce respiratory rate and non-invasive ventilation demand, shorten hospitalization time, and has important value in promoting respiratory function recovery.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: